Taysha Gene Therapies Inc
NASDAQ:TSHA

Watchlist Manager
Taysha Gene Therapies Inc Logo
Taysha Gene Therapies Inc
NASDAQ:TSHA
Watchlist
Price: 2.62 USD -1.87% Market Closed
Market Cap: 660m USD

Net Margin
Taysha Gene Therapies Inc

-1 201.1%
Current
-1 249%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 201.1%
=
Net Income
-86.8m
/
Revenue
7.2m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Taysha Gene Therapies Inc
NASDAQ:TSHA
660m USD
-1 201%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
337.7B USD
7%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 848%
US
Amgen Inc
NASDAQ:AMGN
162.9B USD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
142.2B USD
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.3B USD
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
131.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.4B USD
32%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Taysha Gene Therapies Inc
Glance View

Market Cap
660m USD
Industry
Biotechnology

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas and currently employs 178 full-time employees. The company went IPO on 2020-09-24. The firm is focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). Its portfolio of gene therapy candidates targets a range of neurological indications across three distinct therapeutic categories: neurodegenerative diseases, neurodevelopmental disorders and genetic epilepsies. Its product candidates include TSHA-101, which is being developed for the treatment of giant axonal neuropathy (GAN); TSHA-102, a neurodevelopmental disorder product candidate, which is being developed for the treatment of Rett syndrome; TSHA-118, which is a AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter, and TSHA-105, a gene replacement therapy for the treatment of SLC13A5 deficiency.

TSHA Intrinsic Value
0.55 USD
Overvaluation 79%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 201.1%
=
Net Income
-86.8m
/
Revenue
7.2m
What is the Net Margin of Taysha Gene Therapies Inc?

Based on Taysha Gene Therapies Inc's most recent financial statements, the company has Net Margin of -1 201.1%.

Back to Top